Oppenheimer Boosts Astria Therapeutics (NASDAQ:ATXS) Price Target to $28.00

Astria Therapeutics (NASDAQ:ATXS) had its price target raised by Oppenheimer from $26.00 to $28.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective indicates a potential upside of 198.83% from the company’s previous close.

ATXS has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. TD Cowen began coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 7.1 %

Astria Therapeutics stock opened at $9.37 on Thursday. The stock has a market cap of $528.66 million, a price-to-earnings ratio of -4.48 and a beta of 0.71. The company’s 50-day moving average price is $11.40 and its two-hundred day moving average price is $10.61. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds have recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares during the period. RA Capital Management L.P. boosted its holdings in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after buying an additional 218,518 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.